ClinicalTrials.gg
Not yet recruitingNCT07837687Updated Sep 28, 2026

Effect of Paraffin Wax on Joint Contractures

An interventional study of Paraffin wax and Mineral oil in Burn Joints and Joint Contractures, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Not yet recruiting. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

Limited studies have objectively evaluated the benefit on skin pliability, and relieving itch and pain of paraffin wax, nor has paraffin wax treatment been compared to mineral oil, which is an ingredient in therapeutic paraffin wax. The objective of this study is to examine the immediate impact after paraffin treatment compared with mineral oil controls on joint passive range of motion.

Read the detailed description

The development of joint contractures after a burn injury represents one of the most important morbidities leading to reduced function and quality of life. Paraffin wax is commonly applied to contracted joints for its proposed benefits of increasing skin pliability, and/or relieving itch and pain. This pilot study will determine the feasibility of performing a fully powered study to objectively evaluate whether paraffin wax therapy significantly improves PROM in adult burn survivors with joint contractures of greater than 15% normal joint ROM (upper or lower extremity) compared to equivalent mineral oil treated joint contractures. This study will characterize the changes in PROM, AROM, itch, and pain in adult burn survivors immediately after the application of paraffin wax treatment relative to an intra-individual control scar treated with mineral oil. This will be a prospective, evaluator-blinded, intra-individual, randomized, controlled, pre-post pilot study.

02

Conditions studied

  • Burn Joints
  • Joint Contractures

Browse trials for

Keywords

  • Burns
  • Burn rehabilitation
  • Joint contracture
  • Paraffin wax
03

In context

Burns

905 studies on the registry are indexed under Burns; 164 are open to participants now.

This study's planned enrollment of 12 is below the median of 40 across 663 interventional studies indexed under Burns.

Browse Burns studies →

Lead sponsor

Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult burn survivors (16 years and older)
  • Have joint contractures ≥15% normal PROM at two different joints directly related to their burn injury/scars
  • Are proficient in English and/or French
  • Provide

Exclusion criteria

Exclusion Criteria:

  • Patients who have a cognitive/psychiatric condition that could impair their understanding of the consent process or adherence to protocol procedures
  • Patients with neurological impairments related to their burn injury, such as a drop foot or a drop wrist
  • Patients with pre-burn joint pathology that limited their PROM
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Joint contractures 1 wax, 2 oil

    Two selectionned joint contractures on a single participant. Interventions : one joint with paraffin wax, second joint with mineral oil

    Other: Paraffin wax · Other: Mineral oil

  • Experimental
    Joint contractures 1 oil, 2 wax

    Two selectionned joint contractures on a single participant. Interventions : one joint with mineral oil, second joint with paraffin wax

    Other: Paraffin wax · Other: Mineral oil

Interventions

  • OtherParaffin wax

    Application of Paraffin wax on joint contracture for 20 mins before removal

  • OtherMineral oil

    Application of Mineral oil on joint contracture for 20 mins before removal

06

What researchers measure

Primary outcomes

  1. PROM changes

    Passive range of motion of joint contractures treated with Paraffin wax or Mineral oil, before and after treatment, following regular and revised scar goniometry in extension and flexion

    Time frame: 20 minutes (enrollment to end of visit)

Secondary outcomes

  1. AROM changes

    active range of motion of joint contractures treated with paraffin wax or mineral oil, before and after treatment, following regular and revised scar goniometry in extension and flexion

    Time frame: 20 minutes (enrollment to end of visit)

  2. Pain changes in joint contractures

    Subjective pain of joint contractures treated with paraffin wax or mineral oil (before and after) with Visual analog thermometer

    Time frame: 20 minutes (enrollment to end of visit)

  3. Itch changes in joint contractures

    Subjective itch of joint contractures treated with paraffin wax or mineral oil (before and after) with Visual analog thermometer

    Time frame: 20 minutes (enrollment to end of visit)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 210 non-industry interventional studies with no phase under Burns, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 24 months is above that.

Counting every sponsor, half of 239 studies reached it within 15 months; a quarter within 6 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2026
First posted
Sep 23, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: conditions
1 update, last Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Minor edits only
    + 1 other change: conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07837687
Responsible party
Sponsor
First posted
Sep 23, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Jakub Sawicki, MSc
Contact
jakub.sawicki.chum@ssss.gouv.qc.ca
514-288-8201 ext. 4229
Tomas Gagnon, MSc, PT
Contact
tomas.gagnon.vmed@ssss.gouv.qc.ca
514-974-9702
Bernadette Nedelec, PhD, OT(c)
principal investigator · Centre hospitalier de l'Université de Montréal (CHUM)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion